NTRB logo

Nutriband Inc.

NTRB
Healthcare|Biotechnology|US
$5.55
-0.03 (-0.45%)
Tangible Book / Share
$0.28
Cash / Share
$0.28

About

Nutriband Inc. specializes in developing a diverse range of pharmaceutical products delivered via transdermal patches. The company's most advanced program centers on AVERSA fentanyl, an innovative fentanyl transdermal system engineered to prevent abuse. This extended-release patch provides healthcare professionals and patients with a continuous opioid therapy solution for the ongoing management of chronic pain. Its development pipeline also includes other treatments, such as AVERSA buprenorphine and AVERSA methylphenidate. Additionally, Nutriband is working on exenatide for individuals with type 2 diabetes and follicle stimulating hormone as a treatment for infertility. The company also holds a licensing agreement with Rambam Med-Tech Ltd. to further the development of RAMBAM Closed System Transfer Devices. Nutriband Inc. was founded in 2016 and its main offices are located in Orlando, Florida.

Stock Price

+0.4%(1Y)
1M
-8.3%
3M
+78.5%
6M
+48.0%
YTD
+22.2%
1Y
-7.0%
3Y
+148.9%
5Y
+12.6%

Pipeline Summary

0 total trials
0
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4

Key Facts

Market Cap$67.5M
Employees500 (-75% YoY)
CEOGareth Sheridan
IPO DateOct 1, 2021
Beta1.93
52-Week Range$2.8 – $9.19
Avg Volume52,833
ExchangeNASDAQ

Ownership

Float43.4%
Shares Outstanding12.2M

Recent Insider Trades

Sheridan GarethOTHER
Jan 31, 20250 shares
Sheridan GarethAWARD
Jan 29, 202529,333 shares @ $8.07
Sheridan GarethAWARD
Mar 20, 202497,500 shares @ $2.61
Goodman GeraldAWARD
Jan 23, 202517,667 shares @ $7.34
Goodman GeraldAWARD
Mar 19, 202475,000 shares @ $1.93

Peers

ACETAdicet Bio, Inc.
$28.6M
ACRVAcrivon Therapeutics, Inc. Common Stock
$69.0M
ADAGAdagene Inc.
$75.3M
CRVOCervoMed Inc.
$21.5M
FBIOFortress Biotech, Inc.
$61.7M
GANXGain Therapeutics, Inc.
$43.9M
LITSLite Strategy, Inc.
$31.0M
RLMDRelmada Therapeutics, Inc.
$416.0M
Data last updated: Nov 9, 2026, 04:25 AM